Johnson & Johnson announced Thursday it has reached an agreement with the Trump administration to reduce prescription drug prices for American patients in exchange for exemptions from pharmaceutical tariffs. The agreement makes J&J the 15th major pharmaceutical company to strike
Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Sanofi signed Most Favored Nation pricing agreements with the Trump administration on December 19, marking what a senior White House official described as a shift from “initial
The Trump administration is preparing to launch a new investigation into foreign nations’ drug pricing practices that could pave the way for additional U.S. tariffs on pharmaceutical imports. The probe, expected to be led by the Office of the U.S.
